Boulianne Mélissa, Verret Michael, O'Connor Sarah, Savard Xavier, Neveu Xavier, Marcoux Camille, Costerousse Olivier, Gagnon Marc-Aurèle, Zhang Huixin, Beaulé Laurence, Lamothe-Boucher Frédérique, Turgeon Alexis F
Department of Surgery, CISSS du Bas Laurent, Rimouski, Québec, Canada.
CHU de Québec- Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit (Trauma- Emergency- Critical Care Medicine), Québec city, Canada.
BMC Anesthesiol. 2025 May 10;25(1):235. doi: 10.1186/s12871-025-03105-y.
Although intraperitoneal local anesthetics are commonly used following intra-abdominal surgical procedures, the level of evidence supporting their use for postoperative pain management remains uncertain.
To evaluate the effect of intraperitoneal local anesthetics on postoperative pain following intra-abdominal surgery.
Medline (PubMed), Embase (Embase.com), CENTRAL, Web of science and ClinicalTrials.gov databases were searched from their inception to July 15th, 2022.
Randomized controlled trials comparing IPLA to placebo, usual care or other analgesic regimens among patients of any age undergoing any type of surgery.
Trial selection, data extraction, risk of bias assessment and the certainty of evidence were conducted in duplicate independently. Meta-analyses were performed using random effect models.
The co-primary outcomes were abdominal pain intensity at 6, 12, 24, 48, and 72 h after surgery. Secondary outcomes included postoperative nausea and vomiting, opioid use, recovery of gastrointestinal transit, length of hospital stay, postoperative chronic pain, persistent postoperative opioid use, quality of recovery and adverse events.
A total of 150 trials (n = 11,821 participants were included in our systematic review (97% of trials among adults). Intraperitoneal local anesthetics reduced postoperative pain intensity at 6 h (-0.86 point [95%CI -1.02 to -0.70]), 12 h (-0.74 point [95%CI -0.93 to -0.55]), 24 h (-0.65 point [95%CI -0.82 to -0.48]), and 48 h (-0.51 point [95%CI -0.70 to -0.31]), but not at 72 h (-0.38 point [95%CI -1.04 to 0.27]), with very low to low certainty of evidence. Modelled risk difference for achieving the clinically important effect and subgroup analyses among participants with moderate or high pain showed potential clinically significant effect from IPLA. Opioid use at 24 h (-10.4 mg of oral morphine equivalent [95% CI -13.1 to -7.6]), postoperative nausea and vomiting (RR 0.79 [95% CI -0.71 to 0.88]), and time to gastrointestinal transit recovery (-3.80 h [95% CI -7.54 to -0.07]) were also reduced. We found no association for other outcomes.
Intraperitoneal local anesthetics may be associated with a small analgesic effect following intra-abdominal surgery. Considering the low to very low level of evidence supporting these findings, along with the limited data on adverse effects and long-term outcomes, their adoption as a standard of care intervention cannot be recommended at this stage.
CRD42018115062.
尽管腹腔内局部麻醉剂在腹部外科手术后常用,但支持其用于术后疼痛管理的证据水平仍不确定。
评估腹腔内局部麻醉剂对腹部手术后疼痛的影响。
检索了Medline(PubMed)、Embase(Embase.com)、CENTRAL、Web of science和ClinicalTrials.gov数据库,检索时间从建库至2022年7月15日。
比较腹腔内局部麻醉剂与安慰剂、常规护理或其他镇痛方案的随机对照试验,纳入任何年龄、接受任何类型手术的患者。
试验选择、数据提取、偏倚风险评估和证据确定性由两人独立重复进行。采用随机效应模型进行Meta分析。
共同主要结局为术后6、12、24、48和72小时的腹痛强度。次要结局包括术后恶心和呕吐、阿片类药物使用、胃肠蠕动恢复、住院时间、术后慢性疼痛、持续术后阿片类药物使用、恢复质量和不良事件。
共有150项试验(n = 11821名参与者)纳入我们的系统评价(97%的试验为成人试验)。腹腔内局部麻醉剂在术后6小时(-0.86分[95%CI -1.02至-0.70])、12小时(-0.74分[95%CI -0.93至-0.55])、24小时(-0.65分[95%CI -0.82至-0.48])和48小时(-0.51分[95%CI -0.70至-0.31])降低了术后疼痛强度,但在72小时未降低(-0.38分[95%CI -1.04至0.27]),证据确定性为极低到低。实现临床重要效应的模拟风险差异以及中度或高度疼痛参与者的亚组分析显示,腹腔内局部麻醉剂可能具有潜在的临床显著效应。术后24小时阿片类药物使用量(-10.4毫克口服吗啡当量[95%CI -13.1至-7.6])、术后恶心和呕吐(RR 0.79[95%CI -0.71至0.88])以及胃肠蠕动恢复时间(-3.80小时[95%CI -7.54至-0.07])也有所减少。我们未发现其他结局存在关联。
腹腔内局部麻醉剂在腹部手术后可能具有较小的镇痛效果。鉴于支持这些发现的证据水平低至极低,以及关于不良反应和长期结局的数据有限,现阶段不建议将其作为标准护理干预措施采用。
CRD42018115062。